Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
eNq1mE1z2jAQhu/8Co8PvWFj8kFobTItTVpmkiklYdrphRH2EkSF5OgDSH99ZUwa6MilEehoy353pV09ekfx5WpOvAVwgRlN/Cho+B7QlGWYPiT+8P66fuFfdmrxDC3Q1metoBFETd9LCRIi8YvRYAyIiuD77c1H0P8D9zs1L2bjGaRy5zslMQk+IzG9RXnxjRcvGM68OcgpyxI/V3L91ouF5DqLzpLxnyJHKcTh5s326Gx0uv0+Dgux/1BVAvgNog9GUaBWmqniHKjsIgkPjD9V5HtipY3FAARTPIU+ktM+ZwucQWYMMUFEgFWQyTK7A74gIIsgRvFwls6FlTiaodUAHnvmpN/r0a5cyXqjHrVaUbNxHp23m+2mVSi+tVTmKuhJhOkoap7qKK0QaLgCzh4VEMvi9BmXiDgqCxbd3c5yFIfD497yZ1jkBD0FM5HbLhXiSA8D1/vf3USKGdxzTSSi1+wvfaoICV+Z9XDDC0cZFzjqMkVlBTauB7YL0WVUwqq6onakk6tNL2IQx5P9xaiZ8n01Jji1ZZqmjgIhh4NeNdKOSoMPSMCQu8PBN0wzthTHx8x2WR1ln69JaRTNeRaNmu2L8+jszHoX/dA9VHHGXCnOcgg1gLA4hCs9OmGHEkW3pVnquSmP149rq8NSRKDC7NQt6aIb8dmbOWt1d9uoHDCKfrq6t+2Prwr409360SiNs+RPZe3Q64Lnuhv3JV7u2yQfnTTOLtonp2/QPH/37KITS8dcijoxzIqbITOVMhdvw3C5XAZTJOoC6fUMJvwfp8Clce7HmL9G7ks53Zl6Jx6g9EQlbh2lPi7P0dfV0Xbn7nMJhzrfzf8bh22MIbmCA2pRQt4ZintXx6f7i+11lnZ/hzHuwqwtKpKYUVfOSY2NioedJ7qu9JprQHyZTHDFJUtlX8ZhecHTqcVhcbnTqf0GYYECgw==
EU1qDFRAXJAkWnZk
Listen
